ALNYAlnylam Pharmaceuticals, Inc.

1. May 27, 2026Effective as of June 1, 2026, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly …Director or officer change · Form 8-K
2. Mar 4, 2026Effective March 2, 2026 (the “Grant Date”), the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) granted, following the recommendation of the People, Culture and Compensation Committee (the “Committee”), a special equity award (the “Special Award”) under the Company’s …Director or officer change · Form 8-K
3. Dec 11, 2025On December 10, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) entered into separate, privately negotiated repurchase agreements with certain holders of its 1.00% convertible senior notes due 2027 (the “Notes”) to repurchase for cash (the “Repurchases”) approximately $34.4 million aggregate principal amount of …Other event · Form 8-K
4. Dec 3, 2025Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On December 2, 2025, Michael W. Bonney and Carolyn Bertozzi, Ph.D. provided notice of each of their resignations from the Board of Directors (the “Board”) of Alnylam …Director or officer change · Form 8-K
5. Oct 3, 2025On September 30, 2025 (the “Closing Date”), Alnylam Pharmaceuticals, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) among the lenders party thereto, Bank of America, N.A., as Administrative Agent, and the other parties named therein.Material agreement entered · Form 8-K
6. Sep 12, 2025Indenture and Notes On September 12, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) completed its previously announced offering of $575.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2028 (the “Initial Notes”)Material agreement entered · Form 8-K
7. Sep 10, 2025On September 8, 2025, Alnylam Pharmaceuticals, Inc. (the “Company”) issued a press release relating to the commencement of its proposed offering of convertible senior notes due 2028 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.